Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Rock around the CAR-T cell clock to learn what to watch out for at ASH20!
Using CRISPR screens to find new targets for enhancing T cell fitness
Can we influence T cell fitness and performance by manipulating metabolic processes?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
Commentary on some up and coming biotechs in the oncology space
A look at path to market strategies open to a small biotech in the CAR-T cell space
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
Commentary on Wednesday at JPM17 in San Francisco
A look at the emerging trends we can expect in 2017 for cancer research
Initial impressions of abstracts for ASH16 in San Diego
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
Restoration of hearing in mice by gene transfer is a major breakthrough
